Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06543914 · ClinicalTrials.gov registry record

Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine

A clinical trial of Migraine, sponsored by AbbVie.

Recruiting
Registry status
1,000
Enrollment target
20
Study locations

NCT06543914 is a study of Migraine that is actively recruiting participants, run by AbbVie. The registered enrollment target is 1,000 participants, above the 348-participant average among 102 other Migraine trials with a reported enrollment target (187% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06543914, a study of Migraine, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
1,000 participants
Enrollment target
20
Study locations

Study Summary

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will evaluate the effectiveness of atogepant in treating adult participants with migraine in a real-world setting. Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 1000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study across the world. Participants will receive atogepant oral tablets as prescribed per standard clinical practice and will be followed for 2 years. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Conditions Studied

Migraine

Study Locations (20)

New York

  • Dent Neurologic Institute - Amherst /ID# 267606 - Amherst
  • Northwell Health - Great Neck /ID# 280705 - Great Neck
  • Northwell Health /ID# 267596 - New York

Alabama

  • Neurology and Neurodiagnostics of Alabama /ID# 267614 - Hoover
  • Rehabilitation & Neurological Services /ID# 267612 - Huntsville

California

  • Kenneth Martinez MD, A Medical Corp /ID# 267834 - Aliso Viejo
  • Los Angeles Headache Center /ID# 267570 - Los Angeles

Brussels Capital

  • Cliniques Universitaires UCL Saint-Luc /ID# 270545 - Brussels
  • Universitair Ziekenhuis Brussel /ID# 269799 - Jette

Liege

  • Centre Hospitalier Régional de la Citadelle /ID# 270539 - Liège
  • Groupe Sante CHC - Clinique du MontLegia /ID# 270218 - Liège

Arizona

  • Barrow Neurological Institute - Dignity Health St. Joseph's Hosp and Medical Ctr /ID# 267610 - Phoenix

Florida

  • Alcanza Clinical Research, LLC /ID# 267838 - Lake Mary

Kentucky

  • Norton Cancer Institute - St. Matthews /ID# 267605 - Louisville

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2024-11-26
Est. Completion 2029-02

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06543914

The ClinicalTrials.gov registry entry for NCT06543914 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 348-participant average among 102 other Migraine trials with a reported enrollment target (187% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 0 interventions.

NCT06543914 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT06543914 about?

NCT06543914 is a clinical study titled "Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine". Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will evaluate the effectiveness of atogepant in treating adult participants with migraine in a real-world setting. Atogepant is an app...

What is the current status of trial NCT06543914?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2024-11-26. Estimated completion is 2029-02.

What conditions does trial NCT06543914 study?

This clinical trial studies the following conditions: Migraine.

Who is sponsoring clinical trial NCT06543914?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06543914 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Migraine

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.